Life Sciences Greenhouse of Pennsylvania
VC Fund
Harrisburg, United States
Life Sciences Greenhouse of Pennsylvania is a VC fund in Harrisburg focused on Health Care and Therapeutics. LSGPA partners with a range of institutions, including local research universities, colleges, medical centers, economic development agencies and companies both small and large, to identify needs and opportunities. LSGPA then works to help transfer technologies, to develop new companies, to provide support for existing companies (particularly thoseseeking to expand or relocate), and to ensure that the infrastructure necessary to support a thriving life sciences industry keeps pace with development.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Life Sciences Greenhouse of Pennsylvania invests in
Stages Life Sciences Greenhouse of Pennsylvania invests in
Countries Life Sciences Greenhouse of Pennsylvania invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Marlin Miller
|
|||
Mel Billingsley
|
|||
Jonathan Morris
|
|||
Michele Washko
|
|||
|
Ron Thiboutot
|
Investment Focus
Industry
- Health Care 4 (50%)
- Therapeutics 2 (25%)
- Medical Device 2 (25%)
- Sensor 1 (13%)
- Medical 1 (13%)
Stage
- Series A 2 (25%)
- Series D 2 (25%)
- Funding Round 2 (25%)
- Seed 1 (13%)
- Series B 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Marlin Miller
Board of Director
|
Board of Director | Total investments: 0 | Find email | |
|
Mel Billingsley
President & CEO
|
President & CEO | Total investments: 2 | Find email | |
|
Jonathan Morris
Director
|
Director | Total investments: 0 | Find email | |
|
Michele Washko
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Ron Thiboutot
SVP
|
SVP | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Meduloc
|
Meduloc provides a platform of solutions for small and long bone fractures using internal fixation. The company develops solutions to address the clinical needs of patients and surgeons. | $4M / Series B / Aug 06, 2026 | |
Avisi Technologies
|
Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M / Series A / Feb 25, 2026 | |
|
Avisi Technologies
|
Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $6.3M / Seed / Oct 01, 2023 | |
Micro Interventional Devices
|
Micro Interventional Devices is developing disruptive technologies that are revolutionizing percutaneous and minimally invasive structural heart repair procedures. Their proprietary technology is based on a breakthrough in soft- tissue anchoring and associated delivery devices that enable off-pump procedures. | $20M / Series D / Mar 08, 2019 | |
MacuLogix
|
MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order toprevent vision loss. | $38.7M / Series D / Mar 04, 2019 | |
|
MacuLogix
|
MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order toprevent vision loss. | $500K / Jul 18, 2017 | |
Immunomic Therapeutics
|
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. The company was founded in 2005 and is based in Lancaster, Pennsylvania. | $600K / Mar 28, 2010 | |
Novasentis
|
Novasentis (formerly Strategic Polymer Sciences, Inc.), created the world’s first electro-mechanical polymer (EMP), the thinnest and most flexible haptic actuator and sensor technology today, used to develop mobile and wearable products that come alive with movement and sound. By bridging consumer electronics and sensory interaction, Novasentisenables 4D spatial tactile experiences and next-generation mobile product designs. Novasentis is privately funded. The company is based in San Francisco Bay Area and has offices in Pennsylvania, Korea, and Tokyo. More information on Novasentis is online at www.novasentis.com | $3M / Series A / May 02, 2008 |
Co-Investors
Accanto Partners
2 deals together
Ben Franklin Technology Partners of Southeastern Pennsylvania
2 deals together
Good Growth Capital
2 deals together
MedVenture Partners
2 deals together
Ben Franklin Technology Partners
1 deal together
Ben Franklin Technology Partners of Northeastern Pennsylvania
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Life Sciences Greenhouse of Pennsylvania invest in?
Life Sciences Greenhouse of Pennsylvania invests primarily in Health Care, Therapeutics and Medical Device startups, most often at Series A and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Life Sciences Greenhouse of Pennsylvania?
Public channels for Life Sciences Greenhouse of Pennsylvania include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Life Sciences Greenhouse of Pennsylvania?
The team at Life Sciences Greenhouse of Pennsylvania includes Marlin Miller (Board of Director), Mel Billingsley (President & CEO) and Jonathan Morris (Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
